In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Molecular Staging Inc.

Division of Qiagen NV
www.molecularstaging.com

Latest From Molecular Staging Inc.

Qiagen Buys Molecular Staging: Stalking PCR

Although scientific and clinical interest in molecular diagnostics is at an all-time high, companies are still struggling to find the right business model for the field. Qiagen's recent acquisition of the assets of Molecular Staging, one of the sector's pioneers, reflects the promise and limitations of a field in which competition is fierce, development time is lengthy, and technology is evolving much faster than general market acceptance.
Medical Device Strategy

Protometrix Inc.

Protometrix's microarray technology enables it to produce, purify, and assay thousands of proteins at once on a solid surface. With this skill set, the company believes it can become the first firm able to offer drug developers the ability to scan the entire human proteome in a high-throughput setting.
BioPharmaceutical Research and Development Strategies

ThirdWave Pushes for Parity

Third Wave Technologies wants its Invader technology to be as ubiquitous as PCR. Since a deal with potential buyer Applera fell through two years ago, the company has begun several high-profile collaborations, including one with the Japanese SNP initiative, which now accounts for 50% of revenues. Its efforts appear to be paying off, but the company is fighting an uphill battle in an intensely competitive field.
Medical Device Middle East and Africa

Roche Diagnostics' New Marker Mandate

Roche Diagnostics is the best performing asset at Roche. As the troubled Swiss pharma company suffers through its worst pipeline drought in a decade, Roche Diagnostics is delivering a stellar performance. It is strong across all business segments, from laboratory systems to diabetes to molecular testing. Its challenge: to pull far enough ahead in its traditional businesses to maintain a comfortable lead. Its bigger hurdle, however, is to position itself as a leader in adoption of new genomic and proteomic diagnostic technologies, which is where the industry's future growth lies.
BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Research, Analytical Equipment & Supplies
    • PCR & Amplification Tools
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Qiagen NV
  • Senior Management
  • Michael Sherman, Pres. & CEO
    F. Scott Reding, CFO
    Peter Fuller, SVP, Bus. Dev.
    Jennifer Joiner, VP, Mktg. & Strategic Planning
    Michael Egholm, VP, Research
  • Contact Info
  • Molecular Staging Inc.
    Phone: (203) 772-5000
    300 George St. Ste. 701
    New Haven, CT 06511
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register